MF-766

• Description :

  MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. MF-766 behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. MF-766 can be used for cancer and inflammation diseases research[1][2].

• Product Name Alternative :

  3M-852A

• UNSPSC :

  12352005

• Target :

  Prostaglandin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/mf-766.html

• Purity :

  99.83

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(O)C1=CC=C(C2(NC(C3=CC=CC4=C3N(CC5=CC=C(C(F)(F)F)C=C5)C=C4)=O)CC2)C=C1

• Molecular Formula :

  C27H21F3N2O3

• Molecular Weight :

  478.46

• References & Citations :

  [1]John Colucci, et al. Discovery of 4-[1-[ ([1-[4- (trifluoromethyl) benzyl]-1H-indol-7-yl]carbonyl) amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorg Med Chem Lett|[2]Yun Wang, et al. Combination of EP 4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  EP

• CAS Number :

  [1050656-06-8]